Image Source: Unsplash
An Introduction
The 10 clinical-stage AI-focused (designated with *) and psychedelic compound-based (designated with **) small cap ($400M to $2.0B) drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio were DOWN 13.2%, on average, in June and are now down 23.6%, on average, YTD.Please note: Before proceeding, read Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here’s What You Need to Know to understand why psychedelic stocks are in decline.
The munKNEE Clinical-Stage BioTech Drug Stocks Portfolio
Below are the stock performances of the 10 constituents in the Portfolio for the month of June and their current market capitalizations:
- Area of Focus: specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detect and characterize interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
- Market Capitalization: $823M
- Area of Focus: has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
- Market Capitalization: $1,750M
- Area of Focus: specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- Market Capitalization: $1,390M
- Area of Focus: reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- Market Capitalization: $639M
- Area of Focus: focuses on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Market Capitalization: $219M
- Area of Focus: focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- Market Capitalization: $623M
- Area of Focus: focuses on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Market Capitalization: $495M
- Area of Focus: focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Market Capitalization: $405M
- Area of Focus: develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
- Market Capitalization: $834M
-
- Area of Focus: focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- Market Capitalization: $388M
Summary
On average, the above 10 stocks were DOWN 13.2% in June and are now DOWN 23.6% YTD. The 4 constituents in the Psychedelic Compound-based Drug Stocks Portfolio were DOWN 17.6% while the 6 constituents in the AI-focused Drug Discovery Stocks Portfolio were DOWN 10.4%.More By This Author:12 Largest Cannabis Stocks Declined +11%, On Average, In June
Pure-Play Cybersecurity Software Stocks Up 15% In June
Pure-Play Cloud Computing SaaS Stocks Rebounded In June
